OVERVIEW

The Melton Medical Education, LLC will organize the 2021 International Congress on Myeloproliferative Neoplasms (MPN) at New York Marriott at the Brooklyn Bridge, New York City, New York, United States of America.

This conference is to be held from October 28^th and 29^th of 2021.

Target Audience:
This educational activity is intended for hematologists, medical oncologists, translational scientists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myeloproliferative neoplasms and related disorders.

Course Description:
This year marks the 20^th anniversary of the MPN Congress, an event that has become very popular over the past two decades- providing timely, relevant and meaningful information concerning the diagnosis and treatment of myeloproliferative neoplasms to attendees from around the world. The highly anticipated MPN Congress has always emphasized faculty interaction, audience participation and personal, collegial discussion among attendees, all of which have contributed significantly to the success of this meeting over the years.

The program for the 2021 MPN Congress will offer new information on the prognostic significance of leukocytosis in polycythemia vera, an approach to the differential diagnosis of hereditary erythrocytosis, an update on the clinical status of currently used MPN drugs, as well as new agents of potential value in the MPNs. The role of inflammation in conjunction with the biology and treatment of fatigue in MPN patients, and ruxolitinib-associated weight gain will be discussed.

Other presentations will include the new ELN recommendations for CML treatment, the hypereosinophilias, the status of diagnosis and therapy of mastocytosis, and an update on clinical predictors helpful in MPN transplantation decisions. The differential diagnosis of thrombocytosis and the significance of clonal hematopoiesis, the prognostic role of NGS in MPNs, as well as a review of Covid-19 and its impact on the management of MPNs will round out the program.

At least 300 hematologists/oncologists and other healthcare professionals are expected to attend the in-person, 1.5-day event, with additional attendees joining the meeting virtually. The program features a world class faculty and offers CME credit (including ABIM MOC credit) for physicians and CE for nurses and nurse practitioners.

Educational Objectives:
Upon completion of this educational activity, participants should be able to:
• Understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and related disorders.
• Discuss the role and utilization of current approved therapies in MPNs, including the recent advances in therapeutics.
• Describe the potential role of agents in development for MPNs.
• Assess how to manage symptoms and therapy-associated adverse events for patients with MPNs.
• Outline the current treatment strategies (including first-line therapy, milestones, changing treatment, discontinuation and pregnancy) for patients with chronic myeloid leukemia (CML).